ClinicalTrials.Veeva

Menu

Comparison of PEEP in Acute Decompensated Heart Failure

A

Asan Medical Center

Status

Unknown

Conditions

Mechanical Ventilation Pressure High
Heart Decompensation

Treatments

Other: PEEP

Study type

Interventional

Funder types

Other

Identifiers

NCT04853563
AMC_2021_0433

Details and patient eligibility

About

Little is known about optimal level of positive end-expiratory pressure (PEEP) in patiens who recieved invasive mechanical ventilation for acute decompensated heart failure. We therefore sought to compare clinical outcome according to low versus high PEEP.

Enrollment

120 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subject who was diagnosed with congestive heart failure and objective evidence of pulmonary congestion (pulmonary edema on simple chest radiography or positive B-line on lung ultrasonography AND elevated B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide level) as a reason for invasive mechanical ventilation
  2. Age over 19 years old
  3. Subject who agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the clinical site.

Exclusion criteria

  1. Subject who are on mechanical circulatory support (ECMO, intra-aortic balloon pump, VAD) at the time of randomization
  2. Subject who has cardiac abnormality that requires emergent or urgent percutaneous or surgical valvular procedure
  3. Subject who are on vasoactive or inotropic agents at least moderate dose defined as vasoactive-inotropic score >10
  4. Isolated preload-dependent cardiac dysfunction (isolated right ventricular failure, right ventricular infarction, constrictive pericarditis, cardiac tamponade, severe pulmonary hypertension without LV dysfunction)
  5. Predominant right ventricular failure defined as following; clinical evidence of right ventricular failure by attending physician's discretion including hepatojugular reflux, Kussmaul sign, cardiac liver cirrhosis, hepato/splenomegaly, acites, thronmbocytopenia, etc.
  6. Subject who are not on mechanical ventilation before open heart surgery
  7. Subject who received unwitness cardiopulmonary rescucitation (CPR) or witness CPR lasting more than 30 minutes
  8. Subject who was already diagnosed or is suspected to have hypertophic cardiomyopathy with significant left ventricular outflow tract (LVOT) obstruction
  9. Subject with intracranial hemorrahge or ischemic stroke at the time of randomization
  10. Subject with irreversible neurologic damage or irreversible hepatic failure
  11. Invasive mechanical ventilation lasting more than 24 hours preceding endotracheal intubation
  12. Subject with underlying chronic obstructive pulmonary disease (GOLD classification III or IV) or restrictive pulmonary disease (e.g. interstitial lung disease)
  13. Subject with impaired consciousness that can not perform self coughing and need suction to maintain adequate airway patency
  14. Pregnant and/or lactating women
  15. Subject with life expectancy less than a year
  16. Subject who is not suitable to enrollment by investigator's discretion

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

120 participants in 2 patient groups

High PEEP
Experimental group
Description:
Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 8 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. Thereafter, the PEEP level is adjusted to 1 centimetre of water higher to a minimum PEEP level of 10 with every 30 minutes.
Treatment:
Other: PEEP
Low PEEP
Active Comparator group
Description:
Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 5 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. In this arm, the PEEP level is adjusted to 1 centimetre of water lower to a minimum PEEP level of 3 with every 30 minutes while maintaining a partial pressure of arterial blood oxygen above 65 millimeter of mercury or oxygen saturation \>92% with pulse oxymetry.
Treatment:
Other: PEEP

Trial contacts and locations

1

Loading...

Central trial contact

Minseok Kim

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems